Targeting epilepsy with surgical precision

For the more than 15 million epilepsy patients around the world whose disease is not controlled by medication, the only remaining option is removal of the parts of the brain where seizures originate. Even then, surgery is only 50% effective because accurately pinpointing the brain regions responsible is challenging.

Developed by Johns Hopkins University biomedical engineers, a new method of highlighting the most epileptic parts of the brain could enable not only more accurate diagnosis of the seizure disorder, but also help guide more precise surgical treatment. The team’s study was published recently in Nature Neuroscience and was featured on the cover.

“For these patients, the only available treatment is to surgically remove the brain area responsible for seizures,” said study first author Adam Li, a doctoral student in the laboratory of Sridevi Sarma, associate professor of biomedical engineering. “However, surgery is not as effective as it should be because there is no biomarker that can pinpoint the epileptic brain regions. Our goal was to solve that problem.”

In the study, the team describes how they modeled the dynamics of brain waves to develop a quantitative test that calculates the likelihood that any single brain region would contribute to a seizure. The mathematical model was based on biological experiments that showed changes in brain region connections that render the brain unstable, and thus, prone to seizures. This instability is known as neural fragility. The team then applied this mathematical model to data from electroencephalograms (EEG), computing neural fragility for every EEG electrode.

The next step was developing software that processes data from the EEGs and returns a heatmap showing the neural fragility of channels throughout the brain over time—information that could enable improved diagnosis of epilepsy and help guide surgical treatment of patients leading to higher rates of freedom from seizures. The software obtained a 510k FDA clearance, and Li expects the heatmap will be useful to clinicians when diagnosing epileptic brain regions.

“We are currently in the process of pursuing additional funding to take the product to market,” said Li. “We anticipate that this could take up to one or two years.”

Li and his team released a subset of the anonymous EEG data on openneuro.org, an NIH funded repository for neural data, to help facilitate data sharing and analysis.

The team’s next goal is to replicate its findings in EEG data that was recorded outside of a seizure.

“We want to take snapshots of EEG data without any seizure activity and see if we can pinpoint the epileptic brain regions using only that data,” said Li. “This would be advantageous because then we can leverage the vast amounts of non-seizing EEG data that patients typically have.” This would reduce the time it takes to determine an appropriate treatment, and minimize patient risks associated with intracranial EEG monitoring and hospital costs.

Additional collaborators include researchers and clinicians from the National Institute of Health, University of Maryland Medical Center, Cleveland Clinic, University of Miami, Florida, Jackson Memorial Hospital, and the Johns Hopkins Hospital.

The technology has been licensed through Johns Hopkins Technology Ventures to NeuroLogic Solutions, a startup founded by Sarma. JHTV also is seeking patent protection for the technology.